Henry Schein, Inc. (NASDAQ:HSIC) Receives Average Rating of “Hold” from Analysts

Shares of Henry Schein, Inc. (NASDAQ:HSIC) have been given an average rating of “Hold” by the thirteen analysts that are covering the firm, MarketBeat reports. One investment analyst has rated the stock with a sell recommendation, six have given a hold recommendation and six have issued a buy recommendation on the company. The average 1-year price objective among analysts that have updated their coverage on the stock in the last year is $85.5833.

A number of equities research analysts have recently issued reports on HSIC shares. Mizuho increased their target price on Henry Schein from $81.00 to $88.00 and gave the company a “neutral” rating in a research note on Wednesday, February 25th. Wells Fargo & Company upped their price target on Henry Schein from $76.00 to $87.00 and gave the stock an “equal weight” rating in a report on Wednesday, February 25th. Morgan Stanley lifted their price objective on shares of Henry Schein from $58.00 to $61.00 and gave the company an “underweight” rating in a research note on Wednesday, February 25th. UBS Group boosted their target price on shares of Henry Schein from $79.00 to $87.00 and gave the stock a “neutral” rating in a research report on Wednesday, February 25th. Finally, Weiss Ratings restated a “hold (c)” rating on shares of Henry Schein in a research note on Monday, December 29th.

Henry Schein Price Performance

HSIC opened at $76.50 on Thursday. Henry Schein has a 52-week low of $60.56 and a 52-week high of $89.29. The company has a 50 day moving average of $78.25 and a two-hundred day moving average of $72.77. The company has a market cap of $8.77 billion, a P/E ratio of 23.39, a P/E/G ratio of 2.26 and a beta of 0.88. The company has a quick ratio of 0.76, a current ratio of 1.38 and a debt-to-equity ratio of 0.59.

Henry Schein (NASDAQ:HSIC) last issued its earnings results on Tuesday, February 24th. The company reported $1.34 EPS for the quarter, beating analysts’ consensus estimates of $1.30 by $0.04. Henry Schein had a net margin of 3.02% and a return on equity of 15.16%. The business had revenue of $3.44 billion for the quarter, compared to the consensus estimate of $3.34 billion. During the same quarter last year, the firm posted $1.19 EPS. The business’s revenue for the quarter was up 7.7% compared to the same quarter last year. Henry Schein has set its FY 2026 guidance at 5.230-5.370 EPS. On average, analysts expect that Henry Schein will post 4.74 earnings per share for the current year.

Insider Activity

In other news, EVP Mark E. Mlotek sold 5,925 shares of the firm’s stock in a transaction dated Wednesday, March 4th. The stock was sold at an average price of $80.80, for a total transaction of $478,740.00. Following the completion of the sale, the executive vice president directly owned 80,554 shares in the company, valued at $6,508,763.20. This trade represents a 6.85% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Kurt P. Kuehn sold 2,844 shares of Henry Schein stock in a transaction dated Tuesday, March 10th. The stock was sold at an average price of $78.96, for a total value of $224,562.24. Following the sale, the director directly owned 15,420 shares in the company, valued at approximately $1,217,563.20. The trade was a 15.57% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last quarter, insiders sold 104,556 shares of company stock valued at $8,476,351. Corporate insiders own 1.08% of the company’s stock.

Hedge Funds Weigh In On Henry Schein

A number of institutional investors have recently made changes to their positions in the business. Artisan Partners Limited Partnership grew its position in shares of Henry Schein by 5.7% during the third quarter. Artisan Partners Limited Partnership now owns 6,833,041 shares of the company’s stock worth $453,509,000 after buying an additional 370,837 shares in the last quarter. Invesco Ltd. raised its holdings in Henry Schein by 4.1% in the third quarter. Invesco Ltd. now owns 4,731,698 shares of the company’s stock valued at $314,043,000 after acquiring an additional 184,763 shares in the last quarter. Dimensional Fund Advisors LP raised its holdings in Henry Schein by 8.5% in the fourth quarter. Dimensional Fund Advisors LP now owns 2,816,317 shares of the company’s stock valued at $212,865,000 after acquiring an additional 220,149 shares in the last quarter. Ameriprise Financial Inc. boosted its stake in Henry Schein by 11.3% during the 3rd quarter. Ameriprise Financial Inc. now owns 2,523,014 shares of the company’s stock valued at $167,453,000 after acquiring an additional 256,156 shares during the last quarter. Finally, Southpoint Capital Advisors LP boosted its stake in Henry Schein by 38.9% during the 4th quarter. Southpoint Capital Advisors LP now owns 2,500,000 shares of the company’s stock valued at $188,950,000 after acquiring an additional 700,000 shares during the last quarter. 96.62% of the stock is owned by institutional investors and hedge funds.

Henry Schein Company Profile

Henry Schein, Inc is a leading global distributor of healthcare products and services, primarily serving office-based dental, medical and animal health practitioners. The company operates through three principal segments—Schein Dental, Schein Medical and Animal Health—each offering a comprehensive portfolio of consumable products, equipment, instruments and related value-added services. With a focus on improving practice efficiency and patient care, Henry Schein provides everything from dental restorative materials and orthodontic appliances to vaccines, pharmaceuticals and diagnostic devices for physicians, as well as pet health products and veterinary equipment for animal health professionals.

In addition to its broad product offering, Henry Schein delivers a suite of technology and service solutions aimed at streamlining workflows and enhancing clinical outcomes.